MONMOUTH JUNCTION, N.J., June 29, 2011 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, has appointed Ms. Cheryl Patnick to the position of Vice President of Human Resources. Ms. Patnick had been working with Tris as a consultant for about a year, and will now lead and manage Tris’ human resource activities as an executive of the company.
“Tris is at a point in its evolution where it needs leaders who are willing to take charge of the increasing demands of a rapidly growing company while concurrently supporting the culture that has led to its growth. Cheryl who has been working with me for more than a year is one such leader. We are fortunate to have her joining us in this strategically important position,” said Ketan Mehta, President and CEO of Tris Pharma.
With over 20 years of Human Resources and Merger/Acquisition experience, Cheryl is highly experienced in ensuring workforce maintains a high-level of productivity during times of change and accelerated growth. Most recently, Cheryl served as President of Capella Consultants LLC, where she led the Human Resources and Management consulting group. Prior to Capella, Cheryl spent more than 15 years at Sovereign Bank, the last seven years as Executive Vice President, Human Resources. She is active in the central New Jersey business community as a volunteer and was a recipient of the HR Person of the Year award from the Society of Human Resources Management. She earned a Bachelor of Science in Business Administration, summa cum laude, from the University of Richmond, Virginia.
“I have been working with Ketan and his team at Tris for over one year and admire the team’s leadership, integrity and work ethic. It is truly an environment where individual talent is recognized and aligned with innovation and quality,” said Cheryl Patnick.
About Tris Pharma
Tris Pharma is a specialty pharmaceutical company focused on the research and development of drug delivery technologies based products. Through its OralXR+ platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris’ Nobuse platform provides abuse-deterrence for opioids and other abuse-prone drugs. Tris’ R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, USA. For more information, please visit www.trispharma.com.
SOURCE Tris Pharma
